Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer

Weber,Rebecca; Meister,Michael; Muley,Thomas; Thomas,Michael; Sültmann,Holger; Warth,Arne; Winter,Hauke; Herth,Felix   J.F.; Schneider,Marc  A.

doi:10.3892/ijo.2018.4654

Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer

Authors:
- Rebecca Weber
- Michael Meister
- Thomas Muley
- Michael Thomas
- Holger Sültmann
- Arne Warth
- Hauke Winter
- Felix J.F. Herth
- Marc A. Schneider
View Affiliations

Affiliations: Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, 69126 Heidelberg, Germany, Translational Lung Research Center Heidelberg, member of the German Centre for Lung Research (DZL‑TLRC), 69120 Heidelberg, Germany
Published online on: December 5, 2018 https://doi.org/10.3892/ijo.2018.4654
Pages: 515-526
Copyright: © Weber et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glycodelin [gene name, progesterone associated endometrial protein (PAEP)] was initially described as an immune system modulator in reproduction. Today, it is also known to be expressed in several types of cancer, including non‑small cell lung cancer (NSCLC). In this cancer type, the feasibility of its usage as a follow‑up biomarker and its potential role as an immune system modulator were described. It is assumed that NSCLC tumours secrete glycodelin to overcome immune surveillance. Therefore, targeting glycodelin might be a future approach with which to weaken the immune system defence of NSCLC tumours. In this context, it is important to understand the regulatory pathways of PAEP/glycodelin expression, as these are mostly unknown so far. In this study, we analysed the influence of several inducers and of their downstream pathways on PAEP/glycodelin expression in a human lung adenocarcinoma carcinoma (ADC; H1975) and a human lung squamous cell carcinoma (SQCC) cell line (2106T). PAEP/glycodelin expression was notably stimulated by the canonical transforming growth factor (TGF)‑β pathway in SQCC cells and the PKC signalling cascade in both cell lines. The PI3K/AKT pathway inhibited PAEP/glycodelin expression in the ADC cells and an antagonizing role towards the other investigated signalling cascades is suggested herein. Furthermore, the mitogen‑activated protein kinase kinase (MEK)/extracellular‑signal regulated kinases (ERK) pathway was, to a lesser extent, found to be associated with increased PAEP/glycodelin amounts. The phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT), MEK/ERK pathway and TGF‑β are targets of NSCLC drugs that are already approved or are currently under investigation. On the whole, the findings of this study provide evidence that inhibiting these targets affects the expression of glycodelin and its immunosuppressive effect in NSCLC tumours. Moreover, understanding the regulation of glycodelin expression may lead to the development of novel therapeutic approaches with which to weaken the immune system defence of NSCLC tumours in the future.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	da Cunha Santos G, Shepherd FA and Tsao MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011. View Article : Google Scholar
3	Morris HR, Dell A, Easton RL, Panico M, Koistinen H, Koistinen R, Oehninger S, Patankar MS, Seppala M and Clark GF: Gender-specific glycosylation of human glycodelin affects its contraceptive activity. J Biol Chem. 271:32159–32167. 1996. View Article : Google Scholar
4	Dell A, Morris HR, Easton RL, Panico M, Patankar M, Oehniger S, Koistinen R, Koistinen H, Seppala M and Clark GF: Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. J Biol Chem. 270:24116–24126. 1995. View Article : Google Scholar : PubMed/NCBI
5	Chiu PC, Chung MK, Koistinen R, Koistinen H, Seppala M, Ho PC, Ng EH, Lee KF and Yeung WS: Cumulus oophorus-associated glycodelin-C displaces sperm-bound glycodelin-A and -F and stimulates spermatozoa-zona pellucida binding. J Biol Chem. 282:5378–5388. 2007. View Article : Google Scholar
6	Seppälä M, Koistinen H, Koistinen R, Chiu PC and Yeung WS: Glycosylation related actions of glycodelin: Gamete, cumulus cell, immune cell and clinical associations. Hum Reprod Update. 13:275–287. 2007. View Article : Google Scholar
7	Okamoto N, Uchida A, Takakura K, Kariya Y, Kanzaki H, Riittinen L, Koistinen R, Seppälä M and Mori T: Suppression by human placental protein 14 of natural killer cell activity. Am J Reprod Immunol. 26:137–142. 1991. View Article : Google Scholar : PubMed/NCBI
8	Laird SM, Hill CJ, Warren MA, Tuckerman EM and Li TC: The production of placental protein 14 by human uterine tubal epithelial cells in culture. Hum Reprod. 10:1346–1351. 1995. View Article : Google Scholar
9	Fazleabas AT, Donnelly KM, Srinivasan S, Fortman JD and Miller JB: Modulation of the baboon (Papio anubis) uterine endometrium by chorionic gonadotrophin during the period of uterine receptivity. Proc Natl Acad Sci USA. 96:2543–2548. 1999. View Article : Google Scholar
10	Toth B, Roth K, Kunert-Keil C, Scholz C, Schulze S, Mylonas I, Friese K and Jeschke U: Glycodelin protein and mRNA is downregulated in human first trimester abortion and partially upregulated in mole pregnancy. J Histochem Cytochem. 56:477–485. 2008. View Article : Google Scholar : PubMed/NCBI
11	Tseng L, Zhu HH, Mazella J, Koistinen H and Seppälä M: Relaxin stimulates glycodelin mRNA and protein concentrations in human endometrial glandular epithelial cells. Mol Hum Reprod. 5:372–375. 1999. View Article : Google Scholar
12	Kämäräinen M, Halttunen M, Koistinen R, von Boguslawsky K, von Smitten K, Andersson LC and Seppälä M: Expression of glycodelin in human breast and breast cancer. Int J Cancer. 83:738–742. 1999. View Article : Google Scholar : PubMed/NCBI
13	Hackenberg R, Loos S, Nia AH, Kunzmann R and Schulz KD: Expression of placental protein 14 by the new endometrial cancer cell line MFE-280 in vitro and by endometrial carcinomas in vivo. Anticancer Res. 18(2A): 1153–1158. 1998.PubMed/NCBI
14	Kämäräinen M, Leivo I, Koistinen R, Julkunen M, Karvonen U, Rutanen EM and Seppälä M: Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties. Am J Pathol. 148:1435–1443. 1996.
15	Connor JP, Brudney A, Ferrer K and Fazleabas AT: Glycodelin-A expression in the uterine cervix. Gynecol Oncol. 79:216–219. 2000. View Article : Google Scholar
16	Kämäräinen M, Miettinen M, Seppala M, von Boguslawsky K, Benassi MS, Böhling T and Andersson LC: Epithelial expression of glycodelin in biphasic synovial sarcomas. Int J Cancer. 76:487–490. 1998. View Article : Google Scholar : PubMed/NCBI
17	Ren S, Liu S, Howell PM Jr, Zhang G, Pannell L, Samant R, Shevde-Samant L, Tucker JA, Fodstad O and Riker AI: Functional characterization of the progestagen-associated endometrial protein gene in human melanoma. J Cell Mol Med. 14(6B): 1432–1442. 2010. View Article : Google Scholar
18	Schneider MA, Muley T, Kahn NC, Warth A, Thomas M, Herth FJ, Dienemann H and Meister M: Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. Oncotarget. 7:71285–71297. 2016. View Article : Google Scholar
19	Kunert-Keil C, Steinmüller F, Jeschke U, Gredes T and Gedrange T: Immunolocalization of glycodelin in human adenocarcinoma of the lung, squamous cell carcinoma of the lung and lung metastases of colonic adenocarcinoma. Acta Histochem. 113:798–802. 2011. View Article : Google Scholar
20	Schneider MA, Granzow M, Warth A, Schnabel PA, Thomas M, Herth FJ, Dienemann H, Muley T and Meister M: Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer. Clin Cancer Res. 21:3529–3540. 2015. View Article : Google Scholar
21	Lenhard M, Heublein S, Kunert-Keil C, Vrekoussis T, Lomba I, Ditsch N, Mayr D, Friese K and Jeschke U: Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer. BMC Cancer. 13:6162013. View Article : Google Scholar
22	Scholz C, Heublein S, Lenhard M, Friese K, Mayr D and Jeschke U: Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res Notes. 5:5512012. View Article : Google Scholar
23	Mandelin E, Lassus H, Seppälä M, Leminen A, Gustafsson JA, Cheng G, Bützow R and Koistinen R: Glycodelin in ovarian serous carcinoma: Association with differentiation and survival. Cancer Res. 63:6258–6264. 2003.
24	Cui J, Liu Y and Wang X: The Roles of Glycodelin in Cancer Development and Progression. Front Immunol. 8:16852017. View Article : Google Scholar
25	Morrow DM, Xiong N, Getty RR, Ratajczak MZ, Morgan D, Seppala M, Riittinen L, Gewirtz AM and Tykocinski ML: Hematopoietic placental protein 14. An immunosuppressive factor in cells of the megakaryocytic lineage. Am J Pathol. 145:1485–1495. 1994.
26	Ramachandran S, Ramaswamy S, Cho Ch and Parthasarathy S: Lysophosphatidic acid induces glycodelin gene expression in cancer cells. Cancer Lett. 177:197–202. 2002. View Article : Google Scholar : PubMed/NCBI
27	Bazzi MD and Nelsestuen GL: Differences in the effects of phorbol esters and diacylglycerols on protein kinase C. Biochemistry. 28:9317–9323. 1989. View Article : Google Scholar
28	Sando JJ and Chertihin OI: Activation of protein kinase C by lysophosphatidic acid: Dependence on composition of phospholipid vesicles. Biochem J. 317:583–588. 1996. View Article : Google Scholar
29	Xu JW, Yasui N, Ikeda K, Pan WJ, Watanabe J, Shiotani M, Yanaihara A, Miki T and Yamori Y: Isoflavones regulate secretion of leukemia inhibitory factor and transforming growth factor {beta} and expression of glycodelin in human endometrial epithelial cells. J Endocrinol. 196:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
30	Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguère V, Siegel PM and Bouchard M: GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene. 28:2634–2642. 2009. View Article : Google Scholar
31	Ren S, Howell PM Jr, Han Y, Wang J, Liu M, Wang Y, Quan G, Du W, Fang L and Riker AI: Overexpression of the progestagen-associated endometrial protein gene is associated with microphthalmia-associated transcription factor in human melanoma. Ochsner J. 11:212–219. 2011.
32	Gao J, Mazella J, Seppala M and Tseng L: Ligand activated hPR modulates the glycodelin promoter activity through the Sp1 sites in human endometrial adenocarcinoma cells. Mol Cell Endocrinol. 176:97–102. 2001. View Article : Google Scholar
33	Tabbaa ZM, Zheng Y and Daftary GS: KLF11 epigenetically regulates glycodelin-A, a marker of endometrial biology via histone-modifying chromatin mechanisms. Reprod Sci. 21:319–328. 2014. View Article : Google Scholar
34	Beasley MB, Brambilla E and Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
35	Wittekind C: 2010 TNM system: On the 7th edition of TNM classification of malignant tumors. Pathologe. 31:331–332. 2010.In German. View Article : Google Scholar : PubMed/NCBI
36	Gottschling S, Jauch A, Kuner R, Herpel E, Mueller-Decker K, Schnabel PA, Xu EC, Muley T, Sültmann H, Bender C, et al: Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue. Lung Cancer. 75:45–57. 2012. View Article : Google Scholar
37	Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al: The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar
38	Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar
39	Hodge C, Liao J, Stofega M, Guan K, Carter-Su C and Schwartz J: Growth hormone stimulates phosphorylation and activation of elk-1 and expression of c-fos, egr-1, and junB through activation of extracellular signal-regulated kinases 1-2. J Biol Chem. 273:31327–31336. 1998. View Article : Google Scholar
40	Dhawan P and Richmond A: A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem. 277:7920–7928. 2002. View Article : Google Scholar
41	Holland WS, Chinn DC, Lara PN Jr, Gandara DR and Mack PC: Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 141:615–626. 2015. View Article : Google Scholar :
42	Wada M, Horinaka M, Yamazaki T, Katoh N and Sakai T: The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS One. 9:e1132172014. View Article : Google Scholar
43	Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res. 284:31–53. 2003. View Article : Google Scholar : PubMed/NCBI
44	Riaz A, Huang Y and Johansson S: G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling. Int J Mol Sci. 17:2152016. View Article : Google Scholar
45	Wee P and Wang Z: Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel). 9:92017.
46	Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 305:1163–1167. 2004. View Article : Google Scholar
47	Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE and Jänne PA: Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64:7241–7244. 2004. View Article : Google Scholar
48	Burke JE, Perisic O, Masson GR, Vadas O and Williams RL: Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci USA. 109:15259–15264. 2012. View Article : Google Scholar
49	Orloff MS, He X, Peterson C, Chen F, Chen JL, Mester JL and Eng C: Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet. 92:76–80. 2013. View Article : Google Scholar :
50	de Groot RP, Auwerx J, Karperien M, Staels B and Kruijer W: Activation of junB by PKC and PKA signal transduction through a novel cis-acting element. Nucleic Acids Res. 19:775–781. 1991. View Article : Google Scholar : PubMed/NCBI
51	Jain N, Zhang T, Kee WH, Li W and Cao X: Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J Biol Chem. 274:24392–24400. 1999. View Article : Google Scholar
52	Levy DE and Lee CK: What does Stat3 do. J Clin Invest. 109:1143–1148. 2002. View Article : Google Scholar
53	Ghosh S and Baltimore D: Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature. 344:678–682. 1990. View Article : Google Scholar
54	Shi Y and Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar
55	Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh DS, Yoon MS, Chang CL, Jung JS, et al: Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells. 26:789–797. 2008. View Article : Google Scholar
56	Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, Beer DG, Cope L, Creighton CJ, Danilova L, et al: Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar
57	Brown JS and Banerji U: Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 172:101–115. 2017. View Article : Google Scholar
58	Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: The evolving role of individualized therapy. Cancer Metastasis Rev. 29:37–48. 2010. View Article : Google Scholar